Cushing's Syndrome

Cushing's Syndrome

Thursday 4 June 2020, 16:00 CET 

In this webinar Professor John Newell-Price (UK) discussed the subject of Cushing's Syndrome in the time of COVID-19.

Key messages:

  • Clinical evaluation should guide those needing immediate investigation
  • Strict adherence to COVID-19 protection measures is necessary
  • Alternative ways of consultations (telephone, video) should be used
  • Early discussion with regional/national experts about investigation and management of potential and existing patients is strongly encouraged
  • Patients with moderate or severe clinical features need urgent investigation and management
  • Patients with active Cushing’s syndrome, especially when severe, are immunocompromised and vigorous adherence to the principles of social isolation is recommended
  • In patients with mild features or in whom a diagnosis is less likely, clinical re-evaluation should be repeated at three and six months or deferred until the prevalence of SARS-CoV-2 has significantly decreased; however those individuals should be encouraged to maintain social distancing
  • Diagnostic pathways may need to be very different from usual recommendations in order to reduce possible exposure to SARS-CoV-2
  • When extensive differential diagnostic testing and/or surgery is not feasible, it should be deferred, and medical treatment should be initiated
  • Transsphenoidal pituitary surgery should be delayed during high SARS-CoV-2 viral prevalence
  • Medical management rather than surgery will be the used for most patients since the short- to mid-term prognosis depends in most cases on hypercortisolism rather than its cause; it should be initiated promptly to minimize the risk of infection in these immunosuppressed patients
  • The risk/benefit ratio of these recommendations will need re-evaluation every 2-3 months from April 2020 in each country (and possibly local areas) and will depend on the local health care structure and phase of pandemic.

This webinar has now passed and is available below:

 

Martin Reincke: President-Elect 2019-2021 (chair)

Martin Reincke: President-Elect 2019-2021 (chair)

He studied medicine and graduated at the University of Cologne in 1985, defended his M.D thesis in 1986 and trained there in internal medicine and endocrinology. Early 1990, he went to the National Institutes of Health, Bethesda, USA, as postdoctoral fellow and continued his basic, molecular and clinical research training, receiving significant input by the mentorship of Prof. George Chrousos. Thereafter, he returned as clinical endocrinologist to the University of Würzburg, Germany, joining Prof. Allolio, who had started to build-up a thriving and rapidly growing endocrine department. This intense research period led to a major progress in clinical and translational research in the field of the HPA axis. Soon, the team intensively networked with leading groups in Italy, France, UK, and other parts of Europe and this research has eventually funded by the EU in the framework of the European network for the Study of Endocrine Tumors (ENSAT). Creation of ENSAT provided a seminal and fruitful basis for the continuous flow of clinically relevant discoveries and high-ranking publications. Various national and European grants followed. Between 1998 and 2004, Martin became Professor and Chief of Endocrinology at the Medical Department of the University of Freiburg. In 2004, he was appointed Professor and Chairman of the prestigious Department of Internal Medicine at the Ludwig-Maximilians-University in Munich. Martin was a member of the Executive Committee of the German Endocrine Society, the European Society of Clinical Investigation, and President of the German Endocrine Society (2014-2017). For the European Society for Endocrinology, he has served as member of the Executive Committee Member between 2010 and 2013 and was chair of the Program Organising Committee for the joint congress of the International Society of Endocrinology and European Society of Endocrinology in Florence in 2012. Martin has organised and co-organised many European and international meetings including several European Congresses of Endocrinology and specialised symposia in Cushing’s syndrome and primary aldosteronism (PIPA, IMPROCUSH). Over the years, Martin received several prestigious awards and scholarships, among others the highest scientific award of the Deutsche Gesellschaft für Endokrinologie in 1995, the Schoeller-Junkmann Award. He has been elected as member of the German Academy of Natural Scientists, Leopoldina, in 2008 (German Academy of Sciences), received the prestigious ERC Advanced Grant in 2016 (2.5 mio €), and has been awarded as Distinctive Academic Teacher at his Munich University in 2014. He has been elected as member of the Germany Research Council DFG in 2016, the major research funding body in Germany. Martin has served on several Editorial Boards (JCEM, Hormones), is reviewer of all major journals including Nature Medicine and Genetics, NEJM, Lancet, and Lancet E&D, and is ad hoc reviewer for funding agencies in Italy (AIFA, AIRC), France (ANR, INSERM), UK (BBSRC, MRC), Switzerland (SNF), Israel (GIF), and Australia (NHMRC). He has edited several books and has published more than 400 articles in major international journals, his h-index is 70. Over the last decade his clinical and basic studies have been supported by grants amounting to more than 10 Mio € from various non-profit agencies. His research topics are pituitary and adrenal diseases with a specific focus on pituitary disease, endocrine hypertension, primary aldosteronism and Cushing’s syndrome.

John Newell-Price (UK)

John Newell-Price (UK)

John is Professor of Endocrinology at the University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust, UK, where he is the Lead for Specialised Endocrine Services and for the Sheffield ENETS European Centre of Excellence for Neuroendocrine Tumours. His research interests include glucocorticoids, pituitary and neuroendocrine tumours, and he is widely published in these areas. He was Senior Editor of ‘Clinical Endocrinology’ 2016-2020, and co-author on Clinical Guidelines for Diagnosis of Cushing’s (2008) and Treatment (2015) for the Endocrine Society, and Adrenal Incidentaloma (2016) for the European Society for Endocrinology. He serves on the Endocrine Society’s Board of Directors 2020-2022, and was Chair of the Annual Meeting Steering Committee for Endo 2018, Chicago, USA.

Lynette Nieman (USA) - panel

Lynette Nieman (USA) - panel

Dr. Lynnette Nieman is a Senior Investigator at the National Institutes of Health (NIH) in Bethesda, MD, USA and head of the Endocrine Consult service at the NIH Clinical Center. Dr. Nieman is an active clinical investigator whose research interests include disorders of cortisol deficiency and excess, and female reproduction. She has authored more than 280 publications and sponsored three investigational new drug applications, one of which was licensed in the US and Europe. Dr. Nieman is a past member of the Endocrinology and Metabolism subcommittee of the American Board of Internal Medicine, which writes questions for the certification examination, and is an author and editor of UpToDate. She has received the NIH Director’s Award, NIH Clinical Teacher of the Year Award and the Endocrine Society’s Distinguished Physician award and has provided Congressional testimony. Dr. Nieman served as the President of the Endocrine Society from March 2017 to March 2018.

Antoine Tabarin (France) - panel

Antoine Tabarin (France) - panel

Antoine Tabarin is Professor of Endocrinology and Head of the Department of Endocrinology, Diabetes and Nutrition at the University Hospital of Bordeaux and president of the French university council (CNU) for Endocrinology. He also works in an INSERM Research Unit (U1215) at the Neurocenter Magendie of Bordeaux. His clinical research interests are neuroendocrine tumours with a specific focus on Cushing’s syndrome and adrenal tumours. Her served previously as an editor of the EJE and, among various publications, Antoine Tabarin has been co-author of the 2015 guidelines of the Endocrine Society for the treatment of Cushing's Syndrome and the 2016 guidelines of the ESE for adrenal incidentalomas.

Jerome Bertherat (France) - panel

Jerome Bertherat (France) - panel

Jérôme Bertherat, MD-PhD, received his MD from Paris 6 University and his PhD from Paris XI University, France. He did a post-doctoral fellowship at the Salk Institute (San Diego, CA, USA). He is professor of Endocrinology at Paris Descartes University, Chief of the Endocrinology Department of Cochin Hospital, head of the National Center for Rare Adrenal Diseases and of the research team "Genomics and Signaling of Endocrine Tumors" in the Cochin Institute (INSERM U1016 & CNRS UMR8104), Paris, France. He serves as coordinator of the French National Network for Rare Endocrine Disorders (FIRENDO) and Executive committee member of the International Society of Endocrinology (ISE). He has served as a founding Executive Board member of the European Network for the Study of Adrenal Tumor (ENSAT), deputy Editor of the European Journal of Endocrinology, and member of the Board of the French Endocrine Society (SFE), the Executive committee of the European Society of Endocrinology (ESE) and chair of the Clinical Committee of ESE. His main research specialties include Cushing's syndrome, the genetics of familial endocrine tumors and the molecular genetics of adrenocortical tumors. He is author of more than 350 publications referenced in PubMed, with an H Factor of 74 (Web of Science).

Subscribe to our email alerts